Health

Mix ‘N’ Match COVID Vaccines; Fauci’s Emails Studied; Indian Variant Rising Rapidly

Note that some links may require registration or subscription.

The NIH announced that it has started a trial of mixed COVID-19 vaccine booster regimens.

On a related note, the Public Health Agency of Canada has authorized some mixing of COVID vaccines.

Health officials in Israel say there’s a probable link between Pfizer’s COVID-19 vaccine and cases of myocarditis in young men. (Bloomberg)

U.K. COVID deaths have dropped to zero for the first time since March 2020, prompting calls for the government to push ahead with its planned easing of restrictions later this month. (Bloomberg)

As of Wednesday at 8:00 a.m. EDT, the unofficial COVID-19 toll in the U.S. reached 33,288,014 cases and 595,240 deaths, increases of 23,419 and 672, respectively, since this time a day ago.

COVID-19 is not a threat to the U.S. blood supply, the NIH said.

The FDA warned people not to use the Lepu Medical Technology SARS-CoV-2 Antigen Rapid Test Kit and the Leccurate SARS-CoV-2 Antibody Rapid Test Kit (Colloidal Gold Immunochromatography), saying there is “likely a high risk of false results when using these tests,” neither of which is FDA-approved.

The WHO has authorized CoronaVac, a COVID-19 vaccine made by the Chinese company Sinovac, for emergency use. (New York Times)

“We will get through this together.” — The Washington Post takes a look at the emails of Anthony Fauci, MD, during the height of the COVID-19 pandemic; sometimes he received 1,000 emails in a single day.

Where did the AstraZeneca vaccine rollout go wrong? NPR investigates.

The mRNA technology used in the Pfizer and Moderna coronavirus vaccines is now being investigated for use with other diseases. (CNN)

Vitamin D does not appear to help prevent COVID-19, as some researchers previously thought. (PLOS Medicine)

The COVID-19 variant that first showed up in India is spreading rapidly in the U.S., researchers said. (New York Post)

The coronavirus that causes COVID-19 can infect insulin-producing pancreatic cells and sometimes leads to cell death, a study found. (LiveScience)

In other news:

  • The Supreme Court rejected a Johnson & Johnson appeal over a $2 billion verdict for women who developed cancer after using the company’s talc products. (AP)
  • Novartis’s novel wet age-related macular degeneration drug brolucizumab (Beovu) met its 1-year non-inferiority endpoint compared with Regeneron’s aflibercept (Eylea), the company announced.
  • Novartis also said it received FDA approval for its drug secukinumab (Cosentyx) to treat moderate-to-severe plaque psoriasis in children ages 6 and older.
  • The National Institute of Allergy and Infectious Diseases has started a trial of a universal flu vaccine.
  • The in-person medical school interview may be going away. (Slate)
  • Joyce Frieden oversees MedPage Today’s Washington coverage, including stories about Congress, the White House, the Supreme Court, healthcare trade associations, and federal agencies. She has 35 years of experience covering health policy. Follow

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.